Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055 is registered in ClinicalTrials.gov with Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics as lead sponsor.

NCT NCT06139055
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06139055 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-part, Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Comparative Bioavailability of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
October 2, 2023
Completion date
March 31, 2024
Enrollment
70 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers